Mild to moderate acne vulgaris patients Acne vulgaris,
Conditions
Interventions
Approximately 0.1ml of RT gel with half plain facial mask sheets (no additive substance) were applied and covered under plastic film occlusion for 30 minutes. Then,
the whole face will be illuminated simultaneously with blue light (Omnilux PDTTM LED System) for 20 min. ,Half 13%topical ALA face masks were applied and covered under plastic film occlusion for 30 mi
the whole face will be illuminated simultaneously with blue light (Omnilux PDTTM LED System) for 20 min.
Active Comparator Device,Active Comparator Device
Riboflavin-
Tryptophan Gel PDT,13% 5-
Aminolevulinic Acid PDT
Sponsors
none
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: -Patient aged 18-50 years old -Mild to moderate acne vulgaris patients
Exclusion criteria
Exclusion criteria: -Use of any topical acne treatment or systemic antibiotics within 2 weeks before study initiation. -Use of a systemic retinoid within 9 months before study initiation. -Use of a systemic steroid within 9 months before study initiation. -Using medication that may exacerbate or alleviate acne such as halogens (iodides,chlorides,bromides, halothane), antiepileptics (carbamazepine, phenytoin, phenobarbital), antituberculous (ethionamide, isoniazid, rifampicin), antidepressants (lithium, amoxapine), Ciclosporin,B vitamins (B6, B12, cyanocobalamin). -Recent use of photosensitizing drugs such as tetracyclines, fluoroquinolones, sulfonamides, ibuprofen, ketoprofen, naproxen, furosemide and statins within 6 weeks before study initiation. -History of photosensitivity. -History of keloid. -Presence of any other skin disease that could interfere with the assessment of the acne, such as folliculitis or rosacea. -Presence of any other systemic disease that could affect the acne severity by its presence, such as polycystic ovarian syndrome, or by any medication prescribed for the treatment of the systemic diseases. -Presence of any change in the use of oral contraceptive pills or anti-inflammatory drugs within 3 months before study initiation. -Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global Acne Assessment Score (GAAS) week 0,1,2,3,5, and 7 evaluated by dermatologists ,Fluorescence photography week 0,1,2,3,5, and 7 wood’s lamp ,Adverse Effects week 0,1,2,3,5, and 7 clinical evaluation of erythema, edema, hyperpigmentation, hemorrhage, vesiculation, and exfoliation,Sebum output week 0,1,2,3,5, and 7 Sebumeter® ,Acne lesion counts week 0,1,2,3,5, and 7 evaluated by dermatologists ,Patients’ satisfaction week 0,1,2,3,5, and 7 patients own observation | — |
Secondary
| Measure | Time frame |
|---|---|
| wrinkles, texture, scars, skin color, redness and pigmentation week 0,1,2,3,5, and 7 Antera3D | — |
Countries
Thailand
Contacts
Public ContactSuparat Wangsuwan
Chulabhorn International College of Medicine, Thammasat University
Outcome results
None listed